Novo Nordisk plans to launch its connected insulin pens, the NovoPen 6 and NovoPen Echo Plus, in early 2019. Any provider using diasend and any person using the diasend mobile app will be able to sync data from Novo Nordisk’s connected pens, according to Glooko.
“Until now, data from insulin pens was [sic] self-reported and subject to error, or often simply not captured. Our partnership with Novo Nordisk enables this insulin data to be seamlessly synced to diasend, where patients and providers can easily see the data correlated with glucose levels, activity information and more. This allows much more informed conversations and decisions about the insulin regimen as well as other aspects of the treatment plan” Glooko CEO Russ Johannesson said in prepared remarks.
“Our partnership with Glooko is already helping healthcare professionals to better understand their patients’ diabetes management,” Søren Smed Østergaard, VP of digital health at Novo Nordisk, added. “By integrating our connected, durable insulin pens with the diasend mobile app, we will soon help people manage their disease and access healthcare when they need it.”
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.